Higenamine (Standard)
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases.
For research use only. We do not sell to patients.
- CAS No.: 5843-65-2
- Formula: C16H17NO3
- Molecular Weight:271.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 5843-65-2
-
Molecular Weight 271.31
-
Formula C16H17NO3
-
SMILES
OC1=CC2=C(C(CC3=CC=C(O)C=C3)NCC2)C=C1O
-
Synonyms
Norcoclaurine (Standard); Demethyl-Coclaurine (Standard)
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Fang Y, et al. Discovery of higenamine as a potent, selective and cellular active natural LSD1 inhibitor for MLL-rearranged leukemia therapy. Bioorg Chem. 2021 Apr;109:104723. [Content Brief]
[2]. Ha YM, et al. Higenamine reduces HMGB1 during hypoxia-induced brain injury by induction of heme oxygenase-1 through PI3K/Akt/Nrf-2 signal pathways. Apoptosis. 2012 May;17(5):463-74. [Content Brief]
[3]. Zhu X, et al. Higenamine mitigates interleukin-1β-induced human nucleus pulposus cell apoptosis by ROS-mediated PI3K/Akt signaling. Mol Cell Biochem. 2021 Nov;476(11):3889-3897. [Content Brief]
[4]. Deng T, et al. Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway. J Cardiovasc Pharmacol. 2020 Jun;75(6):535-544. [Content Brief]
[5]. Erasto, Paul et al. Evaluation of Antimycobacterial Activity of Higenamine Using Galleria mellonella as an In Vivo Infection Model. Natural products and bioprospecting vol. 8,1 (2018): 63-69. [Content Brief]
[6]. Dong, Hui et al. Higenamine Promotes Osteogenesis Via IQGAP1/SMAD4 Signaling Pathway and Prevents Age- and Estrogen-Dependent Bone Loss in Mice. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research vol. 38,5 (2023): 775-791. [Content Brief]
[7]. Wu MP, et al. Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of β2-AR/PI3K/AKT signaling pathway. Pharmacol Res. 2016 Feb;104:115-23. [Content Brief]
[8]. Lee SR, et al. Acute oral intake of a higenamine-based dietary supplement increases circulating free fatty acidsand energy expenditure in human subjects. Lipids Health Dis. 2013 Oct 21;12:148. [Content Brief]
[9]. Wen J, et al. Role of Higenamine in Heart Diseases: A Mini-Review. Front Pharmacol. 2022 Jan 10;12:798495. [Content Brief]
[10]. Chen DT, et al. Pharmacological effects of higenamine based on signalling pathways and mechanism of action. Front Pharmacol. 2022 Sep 15;13:981048. [Content Brief]
[11]. Romeo I, et al. The Antioxidant Capability of Higenamine: Insights from Theory. Antioxidants (Basel). 2020 Apr 25;9(5):358. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Higenamine (Standard)
- 5843-65-2
- Norcoclaurine (Standard)
- Demethyl-Coclaurine (Standard)
- Reference Standards
- MAP3K
- MDM-2/p53
- Adrenergic Receptor
- ROS Kinase
- Apoptosis
- β2-AR
- heart failure
- myocyte
- ischemia/reperfusion
- myocardial infarction
- osteoporosis
- Leukemia
- MV4-11
- MOLM-13
- stroke
- CRS
- C6
- HNPCs
- BMSCs
- Inhibitor
- inhibitor
- inhibit